ATLASATLAS fair value
ATLAS has no fair value for this stock today.
ImmunoPrecise Antibodies (HYFT)
ImmunoPrecise Antibodies stock price today, ATLAS forecast and fair value
Healthcare · Biotechnology · NASDAQ
$1.17▲ +1.74%
Prices as of Oct 27, 2026 · USD
Chance of rising in 1 month
46%
that it ends higher than today in 21 sessions
0%coin flip 50%100%
This is just the summary. See everything on ImmunoPrecise Antibodies in ATLAS
ATLAS's own quantitative analysis, all in one place.
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
See everything included
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
On ImmunoPrecise Antibodies
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
And for you
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
Plans from €3.99 a month.
ATLAS's model gives ImmunoPrecise Antibodies a 46% chance of finishing higher a month from now (21 trading sessions) than today: close to a coin flip.
In half of the simulated outcomes the price ends between $1.00 and $1.31; in 9 out of 10, between $0.78 and $1.68. Estimated annual volatility is 76%.
Price, last 12 months (weekly close)
Key numbers
- Market cap
- $63.1M
- 52-week high
- $2.99
- 52-week low
- $0.99
- Revenue (12 months)
- $11.4M
- Revenue growth (YoY)
- -36.6%
- Gross margin
- 58.8%
- Operating margin
- -95.8%
- Net margin
- -89.7%
- Return on equity
- -123.7%
- Free cash flow (12 months)
- $6.2M
- Beta
- 0.83
What this means
ATLAS does not publish a fair value for HYFT right now, but it does show its odds of rising: close to a coin flip.
Over the last 52 weeks HYFT has traded between $0.99 and $2.99. Today it is 60.9% below that high and 18% above its low.
On the business: revenue fell 36.6% year over year; net margin is 89.7%.
Its beta is 0.83: it tends to move less than the market.
About the company
MindWalk Holdings Corp. operates as a bio-native AI company. The company discovers and develops biologics through HYFT Technology and LensAI platform, as well as develops AI drug discovery and biologics through ReefIQ technology.
Want to see everything about ImmunoPrecise Antibodies?
Get started →Plans from €3.99 a month.
Comparable companies
Other companies in the same line of business:
Frequently asked questions
What does ImmunoPrecise Antibodies do?
MindWalk Holdings Corp. operates as a bio-native AI company. The company discovers and develops biologics through HYFT Technology and LensAI platform, as well as develops AI drug discovery and biologics through ReefIQ technology.
What is the chance HYFT goes up next month?
46%: close to a coin flip. In half of the simulated outcomes, HYFT ends the month between $1.00 and $1.31.
How big is ImmunoPrecise Antibodies and what is its P/E ratio?
ImmunoPrecise Antibodies's market capitalization is $63.1M. We do not show a P/E because it has no positive earnings to base one on.
How volatile is HYFT?
ATLAS estimates annual volatility at 76%. In a typical month, half of the outcomes end between $1.00 and $1.31.
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer